Have people really considered what they are interviewing for?

Quote
Anonymous said:
Yes. You are right when you state that physicians don't see Abiify as a very good product for schizophrenia, but I think Alkermes knows that their product will do about as well as Abilify Maintenna. IF they don't understand that then this will be a difficult company to work for. I think the positive about Alkermes is that they have a great pipeline with two great drugs coming out about a year after their LAI Abilify. That's why I am interviewing and would take the job if offered to me. The LAI Abilify will be a dog to promote but I think it is just a place holder for the company until the real drugs are approved and launched in this space the MDD and the other antipsychotic that are coming. I'm willing to take the risk for a big payoff when the MDD drug is approved an launched. Until then, I can stomach selling the LAI Abilify .
Click to expand...

What a fool!
 
























FDA regulations treat branded generics as branded drugs. For example, when Purdue Pharma filed for regulatory approval of OxyContin, it filed a new drug application; FDA approval entitles a branded generic to five years’ market exclusivity, but with less patent protection than there is for a newly developed molecule. By contrast, a company making a generic immediate-release formulation of oxycodone would use an abbreviated new drug application.

 












Anonymous said:
What part of the post don't you understand. This is a company that has no experiencing bringing a drug to market. If the drug is approved, historically the molecule (tab or injection) has little or no market share in Schizophrenia. The branded LAI marketplace is only worth a $1B. So what this all means, your career at ALKS could be short lived.
Click to expand...

Really? In schizophrenia, with NO promotion in schizophrenia, Abilify has a 9% share in schizophrenia. With all indications, it is the most prescribed product in the world. Would you like to try again?

With your really impressive business acumen, I'm so not impressed.
 






Anonymous said:
Really? In schizophrenia, with NO promotion in schizophrenia, Abilify has a 9% share in schizophrenia. With all indications, it is the most prescribed product in the world. Would you like to try again?

With your really impressive business acumen, I'm so not impressed.
Click to expand...

Is the plan to try to grow share in schizophrenia, steal share in schizophrenia or try to sell off label?
 






What is strange is that all of the Otsuka people are interviewing which seems strange??? Sell one injectable and jump to sell the look alike injectable???? Sounds like they need a shot.
 












Anonymous said:
Really? In schizophrenia, with NO promotion in schizophrenia, Abilify has a 9% share in schizophrenia. With all indications, it is the most prescribed product in the world. Would you like to try again?

With your really impressive business acumen, I'm so not impressed.
Click to expand...

Very nice - someone actually understands the truth. Yes, that is 9% with no promotion in schizophrenia for years. You add in everything else, Abilify is the #1 prescribed drug in the US.

What would be really fun is if Abilify doesn't go generic on 4/20 as expected and Otsuka gets another 7 years... Can you guys launch? I don't think so.
 












Anonymous said:
Help me understand... Why couldn't Lauroxil be launched if Abilify doesn't go generic? What difference does that make?
Click to expand...

It could be launched. The question is whether you would have the ability to market the product correctly. Alk doesn't own the trade name Abilify, but you would have supplement for 4 weeks with oral. Even if you are able to call it by molecule name, there is another question of how to get HCP's to write the Rx correctly. On top of that, what happens if you have access to product but are locked out with oral supplementation cause of PA. Legally, any advice would be walking a fine fine line.

If its generic, you can say whatever you want without making claims.
 






Anonymous said:
Very nice - someone actually understands the truth. Yes, that is 9% with no promotion in schizophrenia for years. You add in everything else, Abilify is the #1 prescribed drug in the US.

What would be really fun is if Abilify doesn't go generic on 4/20 as expected and Otsuka gets another 7 years... Can you guys launch? I don't think so.
Click to expand...

In what world are you living?

Abilify isn't even close to #1 prescribed drug in US!!!!! If you want to count dollars, then Ill give it to you. Yet, even that is ???? Against humira. Proair is #1 units driver by brand. And Generic Vicodin is the most prescribed drug.

If Abilify is 9% of schiz market based on $, then that is really sad!!!!! Good lord, Ris, Olan, Cloz, Ser, etc are all generics at cents on the dollar. This would mean that every $ of abilify means there is another 10 patients on the other products.

I'm glad that my HCP's talked me out of this, and I don't need to make decision. Cause you will have buyers remorse with this product.
 












6 Cymbalta 14,487,742
7 Diovan 12,017,281
8 Vyvanse 9,914,366
9 Lantus Solostar 9,858,068
10 Lyrica 9,578,165
11 Spiriva Handihaler 9,498,944
12 Lantus 9,465,389
13 Celebrex 8,961,654
14 Januvia 8,753,604
15 Abilify 8,747,749
16 Namenda 8,290,471
17 Viagra 7,700,014
 






























Top Bottom
Back
Quote